USPTO serial 78225861
THE POWER OF PROTEASOME INHIBITION
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- BEVERLY, JOSETTE MICHELLE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with THE POWER OF PROTEASOME INHIBITION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michael J. Bevilacqua, Esquire
DAVID EHRLICH FROSS ZELNICK LEHRMAN & ZISSU PC866 UNITED NATIONS PLZNEW YORK, NY 10017UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | prescription pharmaceutical preparations for use in the diagnosis or treatment of human diseases and disorders, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, oncologic, auto-immune or immune-related, pulmonary, musculoskeletal, lymphatic, gastrointestinal, bone sensory, viral urinary, renal, infectious, metabolic or central nervous system diagnostic assays and test kits consisting primarily of reagents for clinical, laboratory, medical and chemical use to diagnose, prognose, predict or treat diseases and for providing genomic and proteomic profiles useful in the selection of therapeutics; assays and test kits consisting primarily of reagents for evaluating efficacy of treatments and treatment progress; prognostic test kits consisting primarily of reagents for identifying hereditary risk factors; diagnostic preparations, namely, preparations of extracts, assays, nucleic acids, proteins, polypeptides, and antibodies, and molecular arrays of biological materials for clinical or medical laboratory use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Millennium Pharmaceuticals, Inc.
- Other trademarks owned by Millennium Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Similar marks named THE POWER OF PROTEASOME INHIBITION
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 10, 2007 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 7, 2007 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 9, 2007 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Mar 2, 2007 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 2, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 13, 2006 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 16, 2006 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 16, 2006 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 12, 2005 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Nov 12, 2005 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Nov 10, 2005 | FAXX | FAX RECEIVED | — |
| Oct 28, 2005 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 28, 2005 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Oct 28, 2005 | PAPER RECEIVED | — | |
| Sep 20, 2005 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 9, 2005 | PAPER RECEIVED | — | |
| Sep 7, 2005 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 21, 2005 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 7, 2005 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 7, 2005 | PAPER RECEIVED | — | |
| Nov 29, 2004 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 29, 2004 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 7, 2004 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 18, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 18, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 15, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 26, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 29, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 26, 2004 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 26, 2004 | PAPER RECEIVED | — | |
| Aug 25, 2003 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2003 | DOCK | ASSIGNED TO EXAMINER | — |